The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 07, 2020

Filed:

Nov. 02, 2016
Applicant:

Biontech Ag, Mainz, DE;

Inventors:

Thorsten Klamp, Mainz, DE;

Ugur Sahin, Mainz, DE;

Ozlem Tureci, Mainz, DE;

Michael Koslowski, Frankfurt am Main, DE;

Thomas Hiller, Mainz, DE;

Jens Schumacher, Heidelberg, DE;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/47 (2006.01); A61K 39/00 (2006.01); C07K 14/005 (2006.01); C12N 7/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/4748 (2013.01); A61K 39/0011 (2013.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/523 (2013.01); A61K 2039/5258 (2013.01); A61K 2039/53 (2013.01); A61K 2039/57 (2013.01); A61K 2039/575 (2013.01); A61K 2039/6075 (2013.01); C07K 2319/00 (2013.01); C07K 2319/40 (2013.01); C12N 2730/10123 (2013.01); C12N 2730/10134 (2013.01); C12N 2730/10143 (2013.01); C12N 2730/10171 (2013.01);
Abstract

The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject.


Find Patent Forward Citations

Loading…